|
 |
AgeneraseThis page contains recent news articles, when available, and an overview of Agenerase but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Agenerase (when available) Amprenavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Amprenavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs. For the treatment of HIV-1 infection in combination with other antiretroviral agents Mechanism Of Action: Amprenavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. News Articles on Amprenavir Pharmasset Appoints Michael Rogers as Chief Development Officer - Nov 1, 2007 ...to marketing and has a successful product development record, including Lexiva(R) and the approvals for Agenerase(R), Mepron(R) and Malarone(R). CNNMoney.com Pharmasset Appoints Michael Rogers as Chief Development Officer - Nov 1, 2007 Lexiva(R), Agenerase(R), Mepron(R) and Malarone(R) are registered trademarks of glaxosmithkline. Contact Alan Roemer, Vice President Investor Relations PR Newswire (press release), Abbott Receives US Food and Drug Administration Approval for New ... - Nov 12, 2007 KALETRA should not be given once-daily in combination with Sustiva(R) (efavirenz), Viramune(R) (nevirapine), Agenerase(R) (amprenavir), fosamprenavir, Canada NewsWire (press release), Ensemble Discovery Announces Additions to its Scientific Advisory ... - Nov 7, 2007 Notable among these are Vertex's first two marketed drugs, the HIV protease inhibitors Agenerase® and Lexiva®, as well as the anti-inflammatory compounds Business Wire (press release), Agenerase Discontinuation - Oct 12, 2007 GlaxoSmithKline will be discontinuing the sale of Agenerase (amprenavir) oral solution and 50 mg capsules in the US by the end of October 2007. Facts and Comparisons, FDA Approves Administration of LEXIVA(R) with Lower Dose of ... - Oct 12, 2007 Patients should not take LEXIVA if they have had an allergic reaction to LEXIVA or AGENERASE(R) (amprenavir). High blood sugar, diabetes or worsening of CNNMoney.com New Head-to-Head Study Comparing LEXIVA(R) and Atazanavir Show ... - Jul 25, 2007 PR Newswire (press release),Patients should not take LEXIVA if they have had an allergic reaction to LEXIVA or AGENERASE(R) (amprenavir). High blood sugar, diabetes or worsening of Meeting Highlights From The Committee For Medicinal Products For ... - Jun 26, 2007 Medical News Today (press release),The product information for the following protease inhibitors used in the treatment of AIDS/HIV-infections has now been amended: Agenerase, Crixivan, AIDS and HIV Infection - Jun 26, 2007 KNDO/KNDU,...ddC) Hoffmann-La Roche Zidovudine (Retrovir, AZT, ZDV) GlaxoSmithKline Protease Inhibitors (PIs) Amprenavir (Agenerase, APV) GlaxoSmithKline, Some HIV Drugs May Up Heart Risk - Apr 25, 2007 WebMDExamples of some protease inhibitors are Crixivan, Norvir, Viracept, Agenerase, and Kaletra. Other HIV drugs called nonnucleoside reverse-transcriptase Some HIV Drugs May Up Heart Risk - 26 Apr 2007 WebMDExamples of some protease inhibitors are Crixivan, Norvir, Viracept, Agenerase, and Kaletra. Other HIV drugs called nonnucleoside reverse-transcriptase Fast Pitch: Vertex Pharmaceuticals - Mar 27, 2007 Motley FoolThe firm has two HIV drugs on the market now, Lexiva and Agenerase, which are marketed by partner GlaxoSmithKline (NYSE: GSK). Emergence of resistance mutations: a comparison between drug classes - Dec 19, 2006 Aidsmap,Only one person had used amprenavir (Agenerase), none had used any of the more recent PIs, and ritonavir (Norvir) boosting was also rare – a situation that Vertex HIV Candidate Dropped by Glaxo - Dec 18, 2006 Forbes,The collaboration, started in 1993, has already yielded two other HIV treatments that are already on the market, Agenerase and Lexiva. Emergence of resistance mutations: a comparison between drug classes - Dec 19, 2006 Aidsmap,Only one person had used amprenavir (Agenerase), none had used any of the more recent PIs, and ritonavir (Norvir) boosting was also rare – a situation that Antiretroviral Drugs: A Shot in the Arm to Fight Malaria? Oct 12, 2006 The presence of nelfinavir (Viracept), amprenavir (Agenerase) and the NNRTI nevirapine (Viramune) in thereapies did not hamper the proliferation of the ... -MedIndia, ARV drugs may also help fight malaria Oct 10, 2006 Therapies which included nelfinavir (Viracept), amprenavir (Agenerase) and the NNRTI nevirapine (Viramune) did not inhibit the growth of the malaria parasite. ... -SABC News, Vertex: A Promising Hep-C Play Oct 9, 2006 GSK currently pays Vertex a royalty on sales of Agenerase, Lexiva, and Telzir and will pay additional development milestones for the development of other ... -BusinessWeek The Totally Frightful Issue: Horrific Inspiration Oct 23, 2006 With long, funny names, they could have been drag queens or, maybe, a punk band: Lexiva, Invirase, Saquinavir, Agenerase, and, of course, who could forget The ... -Queerty, Aptivus®(tipranavir) Demonstrates Durable Response Through Nearly ... Oct 15, 2006 ...to outperform a group of ritonavir-boosted comparator protease inhibitors (PIs) that included lopinavir/r (Kaletra®), amprenavir/r (Agenerase®), saquinavir/r ... -Medical News Today (press release), Premarket movers: Microchip Tech falls Sep 20, 2006 The biotech firm, which makes HIV drugs Agenerase and Lexiva, priced on Friday an offering of 9.1 million shares at $33 each and expects to raise $300 million ... -BusinessWeek Vertex prices 9.1M-share offer Sep 15, 2006 ...outstanding. The company makes HIV drugs Agenerase and Lexiva, and has several cancer drugs and hepatitis C treatments in the pipeline. ... -BusinessWeek Updated HIV Treatment Guidelines Now Include Three GSK HIV ... Aug 13, 2006 IMPORTANT SAFETY INFORMATION - You should not take LEXIVA if you have had an allergic reaction to LEXIVA or AGENERASE(R) (amprenavir). ... -International News Service Large analysis shows benefits of starting treatment with efavirenz Aug 22, 2006 The boosted protease inhibitors included were amprenavir (Agenerase), lopinavir (Kaletra), saquinavir (Invirase / Fortovase) and indinavir (Crixivan): newer ... -Aidsmap Updated HIV treatment guidelines now include three GSK HIV ... Aug 14, 2006 ...to others. * You should not take lexiva if you have had an allergic reaction to lexiva or agenerase® (amprenavir). * High blood ... -WebWire Updated HIV Treatment Guidelines Now Include LEXIVA(R) ... Aug 13, 2006 ...to others. Patients should not take LEXIVA if they have had an allergic reaction to LEXIVA or AGENERASE(R) (amprenavir). High blood ... -International News Service The Lancet Publishes 48-week Results From Tipranavir RESIST ... Aug 8, 2006 ...to outperform a group of ritonavir-boosted comparator protease inhibitors (PIs) that included lopinavir/r (Kaletra®), amprenavir/r (Agenerase®), saquinavir/r ... -DG News Co-administration Of LEXIVA With Esomeprazole Does Not Affect ... Jul 9, 2006 HIV to others. You should not take LEXIVA if you have had an allergic reaction to LEXIVA or AGENERASE® (amprenavir). High blood ... -Medical News Today GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48 ... 16 May 2006 HIV to others. You should not take LEXIVA if you have had an allergic reaction to LEXIVA or AGENERASE(R) (amprenavir). High blood ... - PR Newswire ABBOTT STATEMENT ON ADVANCING PEDIATRIC HIV TREATMENT IN ... Mar 13, 2006 Once-daily lopinavir/ritonavir should not be taken with Agenerase(R), Sustiva(R), Viracept(R), Viramune(R), Dilantin(R), Phenobarbital or Tegretol(R). ... - ITNews Abbott Statement on Advancing Pediatric HIV Treatment in ... Mar 13, 2006 Once- daily lopinavir/ritonavir should not be taken with Agenerase®, Sustiva®, Viracept®, Viramune®, Dilantin®, Phenobarbital or Tegretol®. ... - Yahoo! News CROI: etravirine (TMC125) and darunavir (TMC114) in treatment ... Feb 13, 2006 In the control arm, the most commonly used comparator PIs were lopinavir/ritonavir (Kaletra), saquinavir (Invirase), amprenavir (Agenerase) and atazanavir ... - Aidsmap, Multi-component drug delivery system: An emerging trend Feb 8, 2006 Protease Inhibitors (PIs), which include amprenavir (Agenerase), nelfinavir (Viracept), saquinavir (Fortavase), indinavir (Crixivan), ritonavir (Norvir ... - Express Pharma Pulse, Multi-component drug delivery system: An emerging trend Feb 8, 2006 Protease Inhibitors (PIs), which include amprenavir (Agenerase), nelfinavir (Viracept), saquinavir (Fortavase), indinavir (Crixivan), ritonavir (Norvir ... - Express Pharma Pulse Brand Names/Synonyms: Agenerase is also known by the following brand names and/or synonyms141w94, Kvx-478, Agenerase, Prozei,; Agenerase; Amprenavir; Lexiva; VX-478 Drug Category: Agenerase is categorized under the following by the FDA: Anti-HIV Agents; Antibiotics; Anti-HIV Agents; ATC:J05AE05; ATC:J05AE07 Dosage Forms: CAPSULE Absorption: Not Available Interactions: Interactions for Amprenavir: Amprenavir is metabolized in the liver by the cytochrome P450 enzyme system. Amprenavir inhibits CYP3A4. Caution should be used when coadministering medications that are substrates, inhibitors, or inducers of CYP3A4, or potentially toxic medications that are metabolized by CYP3A4. Amprenavir does not inhibit CYP2D6, CYP1A2, CYP2C9, CYP2C19, CYP2E1, or uridine glucuronosyltransferase (UDPGT). HIV Protease Inhibitors: The effect of amprenavir on total drug concentrations of other HIV protease inhibitors in subjects receiving both agents was evaluated using comparisons to historical data. Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir. Similar decreases in Cmax and AUC were seen after the first dose. Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir. Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir. Methadone: Coadministration of amprenavir and methadone can decrease plasma levels ofmethadone. Coadministration of amprenavir and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively. Amprenavir is an inhibitor of cytochrome P450 C.P.A. metabolism and therefore should not be administered concurrently with medications with narrow therapeutic windows that are substrates of CYP3A4. There are other agents that may result in serious and/or life-threatening drug interactions. Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients. Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy. For comprehensive information concerning laboratory test alterations associated with ritonavir, physicians should refer to the complete prescribing information for NORVIR (ritonavir). Chemical IUPAC Name: tetrahydrofuran-3-yl[3-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-benzyl-2-hydroxy-propyl]aminomethanoate : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |